Watch this exclusive video interview from Metro Business Media about Human Genome Sciences (NASDAQ: HGSI). Metro Business Media sat down with Chief Executive Officer, Thomas Watkins to discuss the future of the largest biotechnology companies in the D.C. area. The Rockville-based firm won FDA approval for its ground breaking Lupus drug -- Benlysta -- earlier in the year. Benlysta is the first approved Lupus drug in over 56 years.
Watkins talks about strategic plans with partner Glaxo Smith Kline as well as sales projection for Benlysta, the drug will complete its first full sales year by the second half of 2012.
The company recently announced on December 15, the initiation of another Phase 3 trial (BLISS-SC) for Benlysta, this time in patients with lupus erythematosus. The study will test the efficacy, safety and tolerability in over 800 patients.
BLISS-SC results are expected by 2014 and will be conducted globally in over 200 locations.